HORIZON-MISS-2022-CANCER-01-03
HORIZON-MISS-2022-CANCER-01-03
Programme: Horizon Europe
12 projects · €71,857,021 total EU contribution (project-level) · 143 participating organizations · 26 countries with participants
Total EU funding
Sum of EC max contribution fields for distinct projects in this topic.
€71,857,021
Countries active
Participant organizations by country (headquarters in CORDIS).
- Spain (26)
- France (19)
- Italy (15)
- Germany (11)
- SE (10)
- BE (9)
- Netherlands (6)
- EL (5)
- UK (5)
- CZ (4)
- IE (4)
- CH (3)
- HU (3)
- PT (3)
- RO (3)
- AT (2)
- EE (2)
- IL (2)
- LT (2)
- NO (2)
- PL (2)
- CY (1)
- DK (1)
- FI (1)
- HR (1)
- SI (1)
Open calls
From the EU Funding & Tenders Portal, linked to this topic code when it matches the call identifier. Sync via yarn etl:funding.
No open or forthcoming calls linked to this topic in the database yet.
Top organizations
By number of distinct projects in this topic.
- FUNDACION PRIVADA INSTITUTO DEINVESTIGACION ONCOLOGICA DE VALL-HE4 projects · ES
- NKI AVL4 projects · NL
- CHARITE - UNIVERSITAETSMEDIZIN BERLIN3 projects · DE
- EORTC3 projects · BE
- HUS3 projects · FI
- INSTITUT GUSTAVE ROUSSY3 projects · FR
- REGIONH3 projects · DK
- SYREON3 projects · HU
- CLB2 projects · FR
- IMIM2 projects · ES
- INT2 projects · IT
- MHH2 projects · DE
Projects
Page 1 of 2
| Project | Programme | EU contribution | Total cost | |
|---|---|---|---|---|
International Study for Treatment of Childhood Relapsed ALL 2020 IntReALL 2020 · 101104582 | HORIZON | €6,135,176 | €101,250 | Details |
Pragmatic approach to Adoptive Cell Therapy (ACT) using Tumor Infiltrating Lymphocytes (TIL) in selected solid tumors PragmaTIL · 101104684 | HORIZON | €5,998,840 | €912,219 | Details |
PRecisIon Cancer MEdicine RepurpOsing SystEm Using Pragmatic Clinical Trials PRIME-ROSE · 101104269 | HORIZON | €5,968,725 | €0 | Details |
Lomustine with or without reirradiation for first progression of glioblastoma: a pragmatic randomized phase III study LEGATO · 101103655 | HORIZON | €5,214,734 | €0 | Details |
INTERMITTENT ANDROGEN DEPRIVATION THERAPY IN THE ERA OF ANDROGEN RECEPTOR PATHWAY INHIBITORS; A PHASE 3 PRAGMATIC RANDOMISED TRIAL DE-ESCALATE · 101104574 | HORIZON | €7,185,663 | €100,000 | Details |
A PRECISION MEDICINE TRIAL LEVERAGING BLOOD-BASED TUMOR GENOMICS TO OPTIMIZE TREATMENT IN OPERABLE STAGE III AND HIGH-RISK STAGE II COLON CANCER PATIENTS - THE SAGITTARIUS TRIAL Sagittarius · 101104657 | HORIZON | €5,999,765 | €2,804,752 | Details |
Unravelling the impact of Radiofrequency in liver surgery: the key to decrease local recurrence? LIVERATION · 101104360 | HORIZON | €6,578,064 | €437,188 | Details |
A EUROPEAN MULTI-DISCIPLINARY CLINICAL PROJECT MEANT TO IMPROVE THE MANAGEMENT OF PATIENTS WITH POOR PROGNOSTIC OVARIAN CANCER AFTER NEOADJUVANT CHEMOTHERAPY: RESTORING HOPE, SALVAGING LIVES SALVOVAR · 101104469 | HORIZON | €6,823,071 | €220,875 | Details |
Master Framework and Pragmatic Clinical Trial for Relapse or Refractory Acute Myeloid Leukemia IMPACT- AML · 101104421 | HORIZON | €5,988,403 | €442,500 | Details |
IMPlementing geriatric assessment for dose Optimization of CDK 4/6-inhibitors in older bReasT cAncer patieNTs IMPORTANT · 101104589 | HORIZON | €5,415,013 | €355,000 | Details |